2026 Star Ratings Shift: 4 Strategies for MA Plans

Further change in the Star Ratings program is inevitable, but one thing won’t change: plans that make targeted investments in improving the member experience and clinical outcomes, driven by data, are the most likely to succeed and achieve a higher overall rating. The post 2026 Star Ratings Shift: 4 Strategies for MA Plans appeared first…

Read More

DOJ, Ohio File Antitrust Suit Against OhioHealth Over Payer Contracts

The Department of Justice and the state of Ohio filed an antitrust lawsuit against OhioHealth this week, alleging the health system used “all-or-nothing” contracts that force insurers to include all of its hospitals and physicians. The case highlights federal and state scrutiny of hospital consolidation and restrictive contracting practices — with potential implications for payers,…

Read More

Gilead Sciences Is Acquiring Arcellx and Partnered Multiple Myeloma Drug in $7.8B Deal

Gilead Sciences and Arcellx have been collaborating on the multiple myeloma cell therapy anito-cel since 2022. This therapy was designed to provide better safety, which would be an advantage over Carvykti, the blockbuster multiple myeloma product marketed by Johnson & Johnson and Legend Biotech. The post Gilead Sciences Is Acquiring Arcellx and Partnered Multiple Myeloma…

Read More